Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine : a pooled analysis of four randomised trials
Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4–12 weeks. The planned roll-out in the UK will involve vaccinating...
Main Author: | |
---|---|
Other Authors: | , , , , , , , , , , , , |
Format: | other article |
Language: | eng |
Published: |
2021
|
Subjects: | |
Online Access: | http://hdl.handle.net/10183/230689 |
Country: | Brazil |
Oai: | oai:www.lume.ufrgs.br:10183/230689 |